MV-CEA

AXP000112.1 · Oncolytic virus

Platform
measles virus (Edmonston-NSe vaccine lineage)
Originator
Mayo Clinic
Sponsor
Mayo Clinic

Names

NameTypeSource
MV-CEApreferred name, codecurator, ncit
Carcinoembryonic Antigen-Expressing Measles Virussynonymncit

Virus

Role
Oncolytic
Family
Paramyxoviridae
Virus
measles morbillivirus (NCBI Taxonomy 11234)
Strain
Edmonston-NSe vaccine lineage
Replication
replicating
Modifications
CEA (soluble human carcinoembryonic antigen) cassette inserted as a marker gene
Transgenes
CEACAM5
Route
intraperitoneal
Source
evidence

Cross-references

NCI Thesaurus
C64775

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT00390299Viral Therapy in Treating Patients With Recurrent Glioblastoma MultiformeCompletedPhase 12006-10-232018-11-2923Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Mixed Glioma; Recurrent Glioblastoma
NCT00408590Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedPhase 12004-04-192012-0837Ovarian Cancer; Primary Peritoneal Cavity Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 38216554Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.Nature communications2024cited by trial NCT00390299
PMID 20103634Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.Cancer research2010name in abstract: MV-CEA

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41228258The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management.Cancers2025name in abstract: MV-CEA
PMID 34004331Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.Seminars in cancer biology2022name in abstract: MV-CEA
PMID 36555262Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses.International journal of molecular sciences2022name in abstract: MV-CEA
PMID 28228086Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.Current cancer drug targets2018name in abstract: MV-CEA
PMID 22914495Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.Gene therapy2013name in abstract: MV-CEA
PMID 22796607Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human neuroblastoma through a CD46 and nectin 4-independent pathway.Cancer letters2012name in abstract: Carcinoembryonic Antigen-Expressing Measles Virus
PMID 23009685Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.BMC cancer2012name in abstract: MV-CEA
PMID 18973133Engineered measles virus as a novel oncolytic therapy against prostate cancer.The Prostate2009name in abstract: MV-CEA
PMID 19169959Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.Current opinion in molecular therapeutics2009name in abstract: MV-CEA
PMID 18356818Heat shock protein inhibitors increase the efficacy of measles virotherapy.Gene therapy2008name in abstract: MV-CEA
PMID 18576918Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.Human gene therapy2008name in abstract: MV-CEA
PMID 18056196Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.Clinical cancer research : an official journal of the American Association for Cancer Research2007name in abstract: MV-CEA
PMID 16543921Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.Cancer gene therapy2006name in abstract: MV-CEA
PMID 16551872Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.Clinical cancer research : an official journal of the American Association for Cancer Research2006name in abstract: MV-CEA
PMID 16642271A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.Breast cancer research and treatment2006name in abstract: MV-CEA
PMID 15746945Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer.Cancer gene therapy2005name in abstract: MV-CEA
PMID 12750267Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.Cancer research2003name in abstract: MV-CEA

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01CA200507Optimizing Delivery of Oncolytic Measles Virus Strains with Cell CarriersMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2017–2020name in abstract: MV-CEA
P50CA108961Optimizing Measles Virotherapy in the Treatment of GliomasMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2004–2015name in title: MV-CEA
R01CA154348Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomasMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2011–2014name in abstract: MV-CEA
P50CA136393Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian CancerMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2009–2013name in abstract: MV-CEA
R01CA136547Optimizing Measles Virotherapy in the Treatment of Ovarian CancerMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2009–2012name in abstract: MV-CEA
R21CA123839Measles Virotherapy for Glioblastoma MultiformeMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2006–2007name in abstract: MV-CEA
R21CA103276Measles Virus Therapy for Ovarian CancerMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2003–2004name in abstract: MV-CEA

Notes

Attenuated Edmonston-lineage measles virus engineered to express soluble CEA as a marker of viral gene expression. Dosed intraperitoneally in recurrent ovarian cancer (NCT00408590) and intratumorally/intracavitary in glioma; only the ovarian route is verified here.

How to cite

MV-CEA (AXP000112.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000112.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.